FDA Seeks Comparative Trials, Public Relations Makeover For Obesity Drugs

FDA's research priorities for anti-obesity medicines include gathering data on long-term use of phentermine, particularly in comparison to newer agents, Metabolic & Endocrine Drug Products Division Director David Orloff, MD, told the FDA Science Board Advisory Committee April 22